Abstract
Neutrophils play a vital role in human immune defense, and their dysregulation can cause collateral damage in sepsis and autoimmune diseases. We provide evidence for the involvement of the transient receptor potential vanilloid 2 (TRPV2) in cytokine expression and transmigration in human neutrophils as well as in HL60 cells. These data identify TRPV2 as a candidate target for novel therapeutics regulating neutrophil activity.